Pharmaceuticals
turnover in the nine months was £12,459 million, down 2% AER
but up 2% CER, driven primarily by the growth in HIV sales, which
were up 8% AER, 12% CER to £3,446 million, reflecting further
strong performances by
Triumeq
and
Tivicay
and continued growth from
Juluca
. Respiratory sales
declined 3% AER but grew 1% CER, to £4,937 million, with
growth from the
Ellipta
portfolio and
Nucala
partly
offset by lower sales of
Seretide/Advair
. Sales of Established
Pharmaceuticals fell 10% AER, 6% CER.
In the
US, sales declined 4% AER but grew 2% CER, with growth in the HIV
portfolio and
Benlysta
offsetting declines in Established Pharmaceuticals and Respiratory.
In Europe, sales grew 1% AER but declined 1% CER, with growth in
the Respiratory portfolio only partly offsetting the continued
impact of generic competition to
Epzicom
and
Avodart
.
International sales declined 2% AER but grew 4% CER,
driven
by HIV and the new Respiratory portfolio.
Respiratory
Total
Respiratory sales declined 3% AER but grew 1% CER, with the US down
8% AER, 3% CER. In Europe, sales grew 4% AER, 3% CER and
International sales were flat at AER but up 6% CER, driven
primarily by higher sales in Japan. Growth from the
Ellipta
portfolio and
Nucala
was offset by lower sales of
Seretide/Advair
.
Sales
of
Nucala
were £390
million in the nine months, up 75% AER, 81% CER, continuing to
benefit from the global rollout of the product. US sales of
Nucala
grew 53% AER, 61%
CER to £234 million.
Sales
of
Ellipta
products were up
26% AER, 31% CER, driven by continued growth in all regions. In the
US, sales grew 20% AER, 27% CER, reflecting further market share
gains, partly offset by the impact of continued competitive and
pricing pressures, particularly for ICS/LABAs. In Europe, sales
grew 38% AER, 37% CER, and International sales grew 34% AER, 42%
CER. Sales of
Trelegy
Ellipta
, our new once daily closed triple product,
contributed £79 million to total
Ellipta
sales, benefiting from an
expanded label in the US.
Relvar/Breo Ellipta
sales grew 6% AER, 11% CER, to £756
million, primarily driven by growth in Europe, which was up 23%
AER, 22% CER to £182 million, and in International, which was
up 27% AER, 33% CER to £179 million. In the US,
Breo Ellipta
sales declined 6% AER, 1%
CER, with volume growth of 32%, reflecting continued market share
growth, more than offset by the combined impact of prior period
payer rebate adjustments and increased competitive pricing
pressures.
Anoro Ellipta
sales grew 42% AER, 48% CER to £332 million, driven by gains
in the US. All
Ellipta
products,
Breo
,
Anoro
,
Incruse
,
Arnuity
and
Trelegy
, continued to grow market share
in the US during the nine months.
Sales
of New Respiratory products, comprising
Ellipta
products and
Nucala
, grew 34% AER, 40% CER to
£1,785 million.
Seretide/Advair
sales declined 24% AER, 21% CER to
£1,775 million. Sales of
Advair
in the US declined 34% AER, 30%
CER (6% volume decline and 24% negative impact of price) primarily
reflecting increased competitive pricing pressures. In Europe,
Seretide
sales were down
19% AER, 20% CER to £449 million (12% volume decline and an 8%
price decline). This reflected continued competition from generic
products and the transition of the Respiratory portfolio to newer
products. In International, sales of
Seretide
were down 10% AER, 5% CER, to
£528 million (5% volume decline and no price impact), with a
decline in markets with generic competition partly offset by growth
from certain other developing markets.
HIV
HIV
sales increased 8% AER, 12% CER to £3,446 million in the nine
months, with the US up 7% AER, 13% CER, Europe up 7% AER, 6% CER
and International up 14% AER, 21% CER. The growth was driven by
increased market share for
Triumeq
and
Tivicay
with sales of £1,957
million and £1,187 million, respectively, in the nine months.
Juluca
was approved in the
US in November 2017 and recorded sales of £71 million in the
nine months.
This
growth was partly offset by the impact of generic competition to
Epzicom/Kivexa
,
particularly in Europe. Sales declined 54% AER, 52% CER to £87
million.
Immuno-inflammation
Sales
in the nine months were up 20% AER, 26% CER, primarily driven by
Benlysta,
which grew 21%
AER, 27% CER to £335 million. In the US,
Benlysta
grew 19% AER, 25% CER to
£299 million.
Established
Pharmaceuticals
Sales
of Established Pharmaceuticals were £3,740 million, down 10%
AER, 6% CER, with the decline partly mitigated by favourable prior
period payer rebate adjustments and some post-divestment inventory
sales.
The
Avodart
franchise was down
9% AER, 6% CER to £423 million, primarily due to the loss of
exclusivity in Europe, with the US generic impact now broadly
annualised.
Coreg
franchise
sales
declined 68% AER, 67% CER to £36 million following a generic
Coreg CR
entrant to the US
market in Q4 2017.
Augmentin
sales declined 5% AER but
grew 1% CER to £424 million with improved demand in Emerging
Markets.
|